跳至主要内容
临床试验/IRCT2015092711885N7
IRCT2015092711885N7Other未知

The effect of adding pregabalin to antipsychotics on positive and negative symptoms in patients with schizophrenia: A randomized placebo-controlled double blind trial

Vice chancellor for research, Mazandaran University of Medical Sciences0 个研究点目标入组 48 人开始时间: 待定最近更新:
适应症

试验速览

阶段
未知
状态
Other
发起方
入组人数
48

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional

入排标准

年龄范围
18 years 至 no limit(—)
性别
All

入选标准

  • 1. Diagnosis of schizophrenia according to DSM-V criteria by psychiatrist
  • 2. Age 18 to 65 years
  • 3. Informed consent / guardian for inclusion
  • 4. Treatment with antipsychotics
  • 5. Refractory schizophrenia
  • Exclusion criteria:
  • 1. Other psychiatric disorders axis I or II exist
  • 2. Serious or chronic diseases like renal and liver dysfunction, severe diarrhea, cardiovascular disease, urinary tract infection, head injury
  • 3. Pregnancy
  • 4. Breastfeeding
  • 5. Lack of appropriate contraception in women of reproductive age
  • 6. Substance abuse over the past month
  • 7. Intolerable side effects
  • 8. History of allergy to Pregabalin
  • 9. Change the doses of antipsychotic agents during last two weeks
  • 10. Patient/ guardian’s apply to withdraw from the study

排除标准

  • 未提供

研究者

发起方
Vice chancellor for research, Mazandaran University of Medical Sciences

相似试验